{
    "xml": "<topic id=\"PHP1645\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/rosuvastatin\" basename=\"rosuvastatin\" title=\"ROSUVASTATIN\">\n<title>ROSUVASTATIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_974\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/statins/rosuvastatin\">Rosuvastatin</xref>\n</p>\n<data name=\"vtmid\">406436002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_957233137\" title=\"Statins\">Statins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34581\" title=\"STATINS\" namespace=\"/drug-classes/statins\">STATINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP72658\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/drugs/rosuvastatin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;69 years</p>\n<p>Initially 5&#8211;10&#8239;mg once daily, then increased if necessary to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>\n</li>\n<li outputclass=\"patientGroup adult asian\">\n<p>Adult (patients of Asian origin)</p>\n<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 70 years and over</p>\n<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8211;10&#8239;mg once daily, increased if necessary to 20&#8239;mg once daily, then increased if necessary to 40&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of cardiovascular events in patients at high risk of a first cardiovascular event</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;69 years</p>\n<p>20&#8239;mg once daily.</p>\n</li>\n<li outputclass=\"patientGroup adult asian\">\n<p>Adult (patients of Asian origin)</p>\n<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 70 years and over</p>\n<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Initially 5&#8239;mg once daily with concomitant fibrate increased if necessary to max. 20&#8239;mg daily. For dose adjustments with concomitant atazanavir, clopidogrel, darunavir, dronedarone, eltrombopag, ezetimibe, itraconazole, lopinavir, or tipranavir, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72750\" outputclass=\"cautions\" rev=\"1.9\" parent=\"/drugs/rosuvastatin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Patients of Asian origin</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72596\" outputclass=\"sideEffects\" rev=\"1.6\" parent=\"/drugs/rosuvastatin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Proteinuria</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gynaecomastia</ph>; <ph outputclass=\"sideEffect\">haematuria</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Oedema</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72756\" outputclass=\"breastFeeding\" parent=\"/drugs/rosuvastatin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72615\" outputclass=\"renalImpairment\" parent=\"/drugs/rosuvastatin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Initially 5mg once daily (do not exceed 20&#8239;mg daily) if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72622\" outputclass=\"patientAndCarerAdvice\" rev=\"1.8\" parent=\"/drugs/rosuvastatin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>Patient counselling is advised for rosuvastatin tablets (muscle effects).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1645-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/rosuvastatin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76728\" title=\"Tablet\" namespace=\"/drugs/rosuvastatin/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#bnf_d1e122993\" href=\"#bnf_d1e122993\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/fibrates\" title=\"\" count=\"1\" rel=\"backlink\">bnf_d1e122993</xref>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_594\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/fibrates\" title=\"Fibrates\" count=\"1\" rel=\"backlink\">Fibrates</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#bnf_d1e123571\" href=\"#bnf_d1e123571\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/statins/rosuvastatin\" title=\"\" count=\"1\" rel=\"backlink\">bnf_d1e123571</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78115\" namespace=\"/treatment-summaries/lipid-regulating-drugs\" title=\"Lipid-regulating drugs\" count=\"1\" rel=\"backlink\">Lipid-regulating drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_974\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/statins/rosuvastatin\" title=\"Rosuvastatin\" count=\"1\" rel=\"link\">Rosuvastatin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34581\" namespace=\"/drug-classes/statins\" title=\"STATINS\" count=\"1\" rel=\"link\">STATINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76728\" namespace=\"/drugs/rosuvastatin/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1645",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/rosuvastatin",
    "basename": "rosuvastatin",
    "title": "ROSUVASTATIN",
    "interactants": [
        {
            "id": "bnf_int_974",
            "label": "Rosuvastatin"
        }
    ],
    "vtmid": "406436002",
    "drugClassification": [
        "Statins"
    ],
    "inheritsFromClass": [
        "STATINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures",
                        "html": "Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5&#8211;10 mg once daily, then increased if necessary to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.",
                        "html": "<p>Initially 5&#8211;10&#8239;mg once daily, then increased if necessary to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>",
                        "ageGroup": "18&#8211;69 years"
                    },
                    {
                        "textContent": "Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.",
                        "html": "<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>",
                        "ageGroup": "70 years and over"
                    }
                ],
                "adult asian": [
                    {
                        "textContent": "Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.",
                        "html": "<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>",
                        "ageGroup": "adult (patients of asian origin)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis",
                        "html": "Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.",
                        "html": "<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision)",
                        "html": "Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5&#8211;10 mg once daily, increased if necessary to 20 mg once daily, then increased if necessary to 40 mg once daily, dose to be increased at intervals of at least 4 weeks.",
                        "html": "<p>Initially 5&#8211;10&#8239;mg once daily, increased if necessary to 20&#8239;mg once daily, then increased if necessary to 40&#8239;mg once daily, dose to be increased at intervals of at least 4 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of cardiovascular events in patients at high risk of a first cardiovascular event",
                        "html": "Prevention of cardiovascular events in patients at high risk of a first cardiovascular event"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "20 mg once daily.",
                        "html": "<p>20&#8239;mg once daily.</p>",
                        "ageGroup": "18&#8211;69 years"
                    },
                    {
                        "textContent": "Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.",
                        "html": "<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily.</p>",
                        "ageGroup": "70 years and over"
                    }
                ],
                "adult asian": [
                    {
                        "textContent": "Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.",
                        "html": "<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily.</p>",
                        "ageGroup": "adult (patients of asian origin)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis",
                        "html": "Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.",
                        "html": "<p>Initially 5&#8239;mg once daily, then increased if necessary up to 20&#8239;mg once daily.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Initially 5 mg once daily with concomitant fibrate increased if necessary to max. 20 mg daily. For dose adjustments with concomitant atazanavir, clopidogrel, darunavir, dronedarone, eltrombopag, ezetimibe, itraconazole, lopinavir, or tipranavir, consult product literature.",
                "html": "<p>Initially 5&#8239;mg once daily with concomitant fibrate increased if necessary to max. 20&#8239;mg daily. For dose adjustments with concomitant atazanavir, clopidogrel, darunavir, dronedarone, eltrombopag, ezetimibe, itraconazole, lopinavir, or tipranavir, consult product literature.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Patients of Asian origin",
                "html": "Patients of Asian origin"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Proteinuria",
                        "html": "Proteinuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Gynaecomastia",
                        "html": "Gynaecomastia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "haematuria",
                        "html": "haematuria",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Oedema",
                        "html": "Oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Initially 5mg once daily (do not exceed 20 mg daily) if eGFR 30&#8211;60 mL/minute/1.73 m2.",
                "html": "<p>Initially 5mg once daily (do not exceed 20&#8239;mg daily) if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "Patient counselling is advised for rosuvastatin tablets (muscle effects).",
                "html": "<p>Patient counselling is advised for rosuvastatin tablets (muscle effects).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76728",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "#bnf_d1e122993": [
            {
                "id": "bnf_d1e122993",
                "label": "bnf_d1e122993",
                "type": "#bnf_d1e122993"
            }
        ],
        "interaction": [
            {
                "id": "bnf_int_594",
                "label": "Fibrates",
                "type": "interaction"
            }
        ],
        "#bnf_d1e123571": [
            {
                "id": "bnf_d1e123571",
                "label": "bnf_d1e123571",
                "type": "#bnf_d1e123571"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78115",
                "label": "Lipid-regulating drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_974",
                "label": "Rosuvastatin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34581",
                "label": "STATINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76728",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}